FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged >12yrs) with moderate to severe hidradenitis

FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged >12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP

Links:

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with m… http://buff.ly/dBoHv2p